Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virus-specific CD4+ T cells: ready for direct attack.

Kevin N Heller1, Cagan Gurer, Christian Münz

  • 1Laboratory of Viral Immunobiology and Christopher H. Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021, USA.

The Journal of Experimental Medicine
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Monocyte-derived macrophages drive neurological tissue damage through mitochondrial reactive oxygen species.

Science immunology·2026
Same author

Not so cold after all: tumor infiltrating CD8+ T cells in EBV-positive Burkitt lymphoma are quiescent, not exhausted.

bioRxiv : the preprint server for biology·2026
Same author

Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies.

Journal for immunotherapy of cancer·2026
Same author

Triggering multiple sclerosis: infection with Epstein-Barr virus activates multiple pre-existing autoreactive B and T cells.

Signal transduction and targeted therapy·2026

CD4+ T cells can directly kill infected cells, challenging their traditional role. Efficient processing of Epstein Barr virus (EBV) glycoproteins makes B cells vulnerable to CD4+ T cell attack, informing vaccine development.

Area of Science:

  • Immunology
  • Virology
  • Cellular Biology

Background:

  • CD4+ T cells traditionally orchestrate adaptive immunity.
  • Emerging evidence reveals a direct cytotoxic role for CD4+ T cells.
  • Epstein Barr virus (EBV) infects B cells, establishing lifelong latency.

Discussion:

  • This study demonstrates that Epstein Barr virus (EBV)-transformed B cells are susceptible to lysis by CD4+ T cells.
  • Highly efficient processing of viral glycoproteins for presentation on MHC class II molecules is key to this susceptibility.
  • This mechanism highlights a direct antiviral function of CD4+ T cells.

Key Insights:

  • CD4+ T cells possess direct cytotoxic capabilities against virus-infected cells.
  • Effective antigen processing of EBV glycoproteins by antigen-presenting cells activates CD4+ T cells for cell killing.

Related Experiment Videos

  • MHC class II presentation is crucial for mediating CD4+ T cell-induced lysis of EBV-infected B cells.

    • Outlook:

    • Antiviral vaccine strategies should be designed to stimulate both helper and cytolytic CD4+ T cell responses.
    • Further research into CD4+ T cell-mediated cytotoxicity could reveal new therapeutic targets for viral infections.
    • Understanding this dual role of CD4+ T cells is critical for developing effective immunotherapies.